Journal: BMC Medicine

Article Title: Involvement of sphingosine-1-phosphate receptor 1 in pain insensitivity in a BTBR mouse model of autism spectrum disorder

doi: 10.1186/s12916-024-03722-3

Figure Lengend Snippet: Increased expression of KCNQ2 and KCNQ5 neurons in DRG of BTBR mice. a – c Quantification of KCNQ2 , KCNQ5 , and KCNQ3 mRNA; n = 8–11 mice per group. d – f Representative western blotting results and quantification of the KCNQ2, KCNQ3, and KCNQ5 proteins. n = 8 mice per group. g and h Comparison of the percentage of KCNQ2 + and KCNQ5 + neurons in the BTBR and Con group. n = 8–14 mice per group. i and j Representative images of KCNQ2 and KCNQ5 immunofluorescence in mice DRGs. Scale bars = 100 μm. k and l Distribution of KCNQ2 + and KCNQ5 + neurons of different diameters in the Con and BTBR group. n = 5 mice per group. m XE-991 induced nociceptive behavior in BTBR mice. n = 6 mice per group. All data are shown in bar diagrams, which reflect the arithmetic mean ± standard error of the mean. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, n.s. not significantly different

Article Snippet: The monoclonal antibodies used for immunofluorescence were as follows: anti-S1PR1 (Rabbit, 1:250; ab7707b, Abcam, UK); anti-KCNQ2 (Guinea pig, 1:200; AGP-065, Alomone, Israel); and anti-KCNQ5 (Rabbit, 1:200; APC-155, Alomone, Israel).

Techniques: Expressing, Western Blot, Comparison, Immunofluorescence

Journal: BMC Medicine

Article Title: Involvement of sphingosine-1-phosphate receptor 1 in pain insensitivity in a BTBR mouse model of autism spectrum disorder

doi: 10.1186/s12916-024-03722-3

Figure Lengend Snippet: M channel and abnormal MAPK cAMP/PKA signaling pathways rescued by inhibition of S1PR1 in mice DRGs. a – c Quantification of KCNQ2 , KCNQ3 , and KCNQ5 mRNA levels after the W146 intervention. n = 6–12 mice per group. d – f Representative western blotting results and quantification of the KCNQ2, KCNQ3, and KCNQ5 proteins after W146 intervention. n = 8 mice per group. g and h Representative images of KCNQ2 and KCNQ5 immunofluorescence in mice DRGs. Scale bars = 100 μm. Comparison of the percentage of KCNQ2 + neurons in the BTBR + W146 and BTBR group; n = 6–9 mice per group. i – l Representative western blotting results and quantification of P-ERK/ERK, P-P38/P38, P-PKA/PKA, and P-PKC/PKC proteins. n = 8 mice per group. All data are shown in bar diagrams, which reflect the arithmetic mean ± standard error of the mean. * p < 0.05, ** p < 0.01, *** p < 0.001, n.s. not significantly different

Article Snippet: The monoclonal antibodies used for immunofluorescence were as follows: anti-S1PR1 (Rabbit, 1:250; ab7707b, Abcam, UK); anti-KCNQ2 (Guinea pig, 1:200; AGP-065, Alomone, Israel); and anti-KCNQ5 (Rabbit, 1:200; APC-155, Alomone, Israel).

Techniques: Inhibition, Western Blot, Immunofluorescence, Comparison

Journal: Cancer Management and Research

Article Title: DSG2 and c-MYC Interact to Regulate the Expression of ADAM17 and Promote the Development of Cervical Cancer

doi: 10.2147/CMAR.S456548

Figure Lengend Snippet: DSG2 is up-regulated in human cervical cancer and is associated with a poor prognosis. ( A ) Higher expression of DSG2 was found in cervical cancer samples than the normal tissues (based on TCGA database). ( B ) Kaplan–Meier plots of overall survival for cervical cancer samples with high/low DSG2 expression from the TCGA database.

Article Snippet: Primary antibodies against DSG2 (21,880-1-AP, 1:1000, Proteintech), ADAM17 (29,948-1-AP, 1:2000, Proteintech) and c-MYC (67,447-1-Ig, 1:5000, Proteintech) were used.

Techniques: Expressing

Journal: Cancer Management and Research

Article Title: DSG2 and c-MYC Interact to Regulate the Expression of ADAM17 and Promote the Development of Cervical Cancer

doi: 10.2147/CMAR.S456548

Figure Lengend Snippet: Knockdown of DSG2 in cervical cancer cells. ( A ) The knockdown efficiency of the three groups of siRNA in HeLa cells was 84%, 86% and 28%, respectively. ( B and C ) The specificity and validity of the siRNA knockdown of DSG2 expression in HeLa and SiHa cells was verified by qPCR ( B ) and WB ( C ). *P < 0.05, **P < 0.01.

Article Snippet: Primary antibodies against DSG2 (21,880-1-AP, 1:1000, Proteintech), ADAM17 (29,948-1-AP, 1:2000, Proteintech) and c-MYC (67,447-1-Ig, 1:5000, Proteintech) were used.

Techniques: Knockdown, Expressing

Journal: Cancer Management and Research

Article Title: DSG2 and c-MYC Interact to Regulate the Expression of ADAM17 and Promote the Development of Cervical Cancer

doi: 10.2147/CMAR.S456548

Figure Lengend Snippet: Knockdown of DSG2 inhibited proliferation and migration of cervical cancer cells. ( A ) The proliferation of HeLa and SiHa cells after knockdown of DSG2 was measured using CCK-8 assay. ( B ) The effect of DSG2 knockdown on cervical cancer cell clone formation. ( C ) The migration ability of HeLa and SiHa cells after knockdown of DSG2 was measured using Transwell assay. *P < 0.05, **P < 0.01, ***P < 0.001.

Article Snippet: Primary antibodies against DSG2 (21,880-1-AP, 1:1000, Proteintech), ADAM17 (29,948-1-AP, 1:2000, Proteintech) and c-MYC (67,447-1-Ig, 1:5000, Proteintech) were used.

Techniques: Knockdown, Migration, CCK-8 Assay, Transwell Assay

Journal: Cancer Management and Research

Article Title: DSG2 and c-MYC Interact to Regulate the Expression of ADAM17 and Promote the Development of Cervical Cancer

doi: 10.2147/CMAR.S456548

Figure Lengend Snippet: ADAM17 is up-regulated in human cervical cancer and is associated with a poor prognosis. ( A ) The bioinformatics analysis of TCGA-CHOL dataset showed the positive expression correlation between DSG2 and ADAM17. ( B ) Higher expression of ADAM17 was found in cervical cancer samples than the normal tissues (based on TCGA database). ( C ) Kaplan–Meier plots of overall survival for cervical cancer samples with high/low ADAM17 expression from the TCGA database.

Article Snippet: Primary antibodies against DSG2 (21,880-1-AP, 1:1000, Proteintech), ADAM17 (29,948-1-AP, 1:2000, Proteintech) and c-MYC (67,447-1-Ig, 1:5000, Proteintech) were used.

Techniques: Expressing

Journal: Cancer Management and Research

Article Title: DSG2 and c-MYC Interact to Regulate the Expression of ADAM17 and Promote the Development of Cervical Cancer

doi: 10.2147/CMAR.S456548

Figure Lengend Snippet: DSG2 regulates the expression of ADAM17 in cervical cancer. ( A ) The effect of DSG2 knockdown on ADAM17mRNA expression was detected by qPCR. ( B ) The effect of DSG2 knockdown on ADAM17 protein expression was detected by WB. ( C ) The interaction between DSG2 and c-MYC was detected by Co-IP assay. ***P < 0.001.

Article Snippet: Primary antibodies against DSG2 (21,880-1-AP, 1:1000, Proteintech), ADAM17 (29,948-1-AP, 1:2000, Proteintech) and c-MYC (67,447-1-Ig, 1:5000, Proteintech) were used.

Techniques: Expressing, Knockdown, Co-Immunoprecipitation Assay

Journal: Cancer Management and Research

Article Title: DSG2 and c-MYC Interact to Regulate the Expression of ADAM17 and Promote the Development of Cervical Cancer

doi: 10.2147/CMAR.S456548

Figure Lengend Snippet: DSG2 regulates cervical cancer development by interacting with c-MYC. ( A ) HeLa cells were transfected with pcDNA(3.1)-DSG2 overexpression plasmid, and the mRNA level of DSG2 was detected by qPCR. ( B ) HeLa cells were transfected with pcDNA(3.1) overexpression plasmid, and the protein level of DSG2 was detected by WB. ( C and D ) DSG2 overexpressed HeLa cells were treated with a C-MYC inhibitor (10,058-F4, 50 μM), and the proliferative activity and migration ability were detected by CCK-8 ( C ) and clonal formation assay ( D ). ( E ) DSG2 overexpressed HeLa cells were treated with a C-MYC inhibitor, and ADAM17 protein expression was detected by WB.*P < 0.05, **P < 0.01, ***P < 0.001.

Article Snippet: Primary antibodies against DSG2 (21,880-1-AP, 1:1000, Proteintech), ADAM17 (29,948-1-AP, 1:2000, Proteintech) and c-MYC (67,447-1-Ig, 1:5000, Proteintech) were used.

Techniques: Transfection, Over Expression, Plasmid Preparation, Activity Assay, Migration, CCK-8 Assay, Tube Formation Assay, Expressing